With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
Serious Gram-negative (GN) pathogens are clinically-important pathogens in both the hospital and outpatient settings. GN pathogens are often acquired in healthcare facilities, and therefore have a…
The Chinese market for hepatocellular carcinoma (HCC) therapies represents an increasingly lucrative space for many pharmaceutical companies. Although the high prices demanded by targeted brands…
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…
The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…
Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…
Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…
Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…
Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…